Volume 13, Number 4Review ArticlesReview of the Literature: PCA3 for Prostate Cancer Risk Assessment and PrognosticationDiagnosis ReviewAlan W PartinStacy LoebProstate cancer antigen 3 (PCA3) is a novel urine-based prostate cancer biomarker that has recently been studied extensively for the prediction of prostate biopsy results and treatment outcomes. Numerous studies have demonstrated that urinary PCA3 scores are predictive of prostate cancer detection on both initial and repeat biopsy. There is conflicting evidence on the relationship between PCA3 with aggressive tumor features and treatment outcomes. This article reviews the current evidence on PCA3 as a marker for prostate cancer detection and prognosis. [Rev Urol. 2011;13(4):e191-e195 doi: 10.3909/riu0539] © 2011 MedReviews®, LLCProstate cancerProstatectomyProstate cancer antigen 3Risk assessment
Volume 13, Number 1Review ArticlesPostprostatectomy Erectile Dysfunction: The Role of Penile RehabilitationManagement UpdateBrian P DeFadeCulley C CarsonMichael J Kennelly"Radical prostatectomy has become the gold standard for the treatment of prostate cancer in patients who have a longer than 10-year life expectancy. Surgical treatment has led to severe quality-of-life issues in these patients, especially urinary incontinence and erectile dysfunction (ED). This article reviews the etiology and pathophysiology of postprostatectomy ED, and current management strategies for these patients. [Rev Urol. 2011;13(1):6-13 doi: 10.3909/riu0501]"Erectile dysfunctionPenile rehabilitationProstatectomy